Clinical trial NCT04449198: Type 1 Diabetes, Endothelin, and Skeletal Muscle Mitochondrial Dysfunction: The Role of Sirtuin-1
Official title: Type 1 Diabetes, Endothelin, and Skeletal Muscle Mitochondrial Dysfunction: The Role of Sirtuin-1
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: EARLY_PHASE1
Conditions: Type 1 Diabetes
Keywords: diabetes
heart disease
muscle function
blood vessels
Lead sponsor: Augusta University
Sponsor class: OTHER
First posted: 2020-06-26
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The proposed study is designed to test the hypothesis that treatment of resveratrol for 12 weeks will improve both endothelin-B receptor (aim 1) and skeletal muscle mitochondrial function (aim 2) in people with type 1 diabetes.

Detailed description: Preliminary data from the investigators' laboratory demonstrate a negative relationship between hemoglobin A1c (HbA1c) and ETBR function, supporting ETBR may be dysfunctional in the presence of T1D. Using near infrared spectroscopy (NIRS) to non-invasively assess muscle function, the investigators have also observed reduced skeletal muscle mitochondrial function in people with T1D compared to healthy controls. In addition, reduced circulating Sirt1 is associated with both ETBR and skeletal muscle mitochondrial dysfunction in the general population. For the current application, the investigators propose to utilize intradermal microdialysis and NIRS as unique, novel, and minimally invasive methods to investigate ETBR and skeletal muscle mitochondrial function, respectively, in people with T1D. Accordingly, the central hypothesis is that increasing circulating Sirt1 with oral supplementation of resveratrol will improve both ETBR function and mitochondrial skeletal muscle function, reducing overall CVD risk (Figure 1). The investigators will test this hypothesis with the following specific aims:

Aim 1: To test the hypothesis that an increase in Sirt1 will improve ETBR function in people with T1D. The investigators will evaluate ETBR function and circulating Sirt1 at baseline and after a 12-week treatment of resveratrol or placebo. Based on preliminary data, the investigators predict that people with T1D will have ETBR dysfunction compared to controls. In addition, the investigators predict that increasing Sirt1 following resveratrol treatment will improve ETBR function, whereas no change will occur with placebo.

Aim 2: To test the hypothesis that an increase in Sirt1 will improve skeletal muscle mitochondrial function and lower HbA1c in people with T1D. A non-invasive assessment of skeletal muscle function will be performed on people with T1D before and after 12-weeks of treatment with resveratrol or placebo. Compared to controls, the investigators predict that people with T1D will have skeletal muscle dysfunction. Following 12 weeks of resveratrol, the investigators predict that the increase in circulating Sirt1 will improve skeletal muscle function. Additionally, the investigators predict the improved skeletal muscle function will contribute to a subsequent decrease in HbA1c in people with T1D.

Eligibility criteria: Inclusion Criteria:

* Men and premenopausal women
* All races
* Clinical diagnosis of insulin-dependent type 1 diabetes (patients only)

Exclusion Criteria:

* Clinical diagnosis of hepatic, cardiovascular, or renal disease
* Uncontrolled diabetes (HbA1C \>12%)
* Diabetic complications (i.e. neuropathy)
* Uncontrolled hypertension (\>140/90 mm Hg on therapy)
* Pregnancy
* Use of vasoactive medications

Primary outcomes:
measure: Change in AUC for ET-1 + BQ-123
timeFrame: Measure taken at Baseline and post 12 weeks
measure: Skeletal Muscle Mitochondrial Function
timeFrame: Measure taken at Baseline and post 12 weeks
Secondary outcomes:
measure: Change in Percentage Flow-Mediated Dilation (FMD)
timeFrame: Measure taken at Baseline and post 12 weeks
measure: Change in Pulse Wave Velocity (PWV)
timeFrame: Measure taken at Baseline and post 12 weeks
measure: Change in Post Occlusive Reactive Hyperemia (PORH)
timeFrame: Baseline and post 12 weeks
Other outcomes:
Locations:
city: Augusta
country: United States
facility: Augusta University/Georgia Prevention Institute/ Laboratory of Integrative and Exercise Physiology
state: Georgia
Study officials:
References: